GARDP partners with Japanese pharmaceutical in pursuit of new antibiotics

March 12, 2020

[Geneva/Tokyo - 12 March 2020] The Global Antibiotic Research and Development Partnership (GARDP) has today announced an agreement with Daiichi Sankyo for GARDP to access and screen the Daiichi Sankyo chemical library. The library will be tested by Institut Pasteur Korea with the goal of discovering novel antibacterial compounds. The agreement sees Daiichi Sankyo join Eisai and Takeda as part of an AMR Screening Consortium, which aims to accelerate GARDP efforts to identify compounds for development into treatments for drug-resistant infections.

Antimicrobial resistance is a major and rapidly growing public health concern and has been identified by the World Health Organization (WHO) as among the greatest threats to global health. Each year 700,000 people die due to drug-resistant infections. Without urgent action to develop new antimicrobial treatments, this number is projected to increase exponentially.

GARDP will test compounds from the Daiichi Sankyo chemical library, which have never been screened for antibacterial activity, against drug-resistant bacteria identified as a critical priority on the WHO priority pathogens list. Through the screening, GARDP hopes to identify novel compounds for further optimization and development.

"GARDP's partnership with Daiichi Sankyo gives GARDP the opportunity to screen a proprietary library that otherwise would not be tested for antibacterial activity," said Laura Piddock, GARDP Director of Scientific Affairs. "The AMR Screening Consortium is a wonderful opportunity to discover novel compounds to potentially develop into life-saving treatments for drug-resistant infections."
About the AMR Screening Consortium

The AMR Screening Consortium is an agreement between the Global Antibiotic Research and Development Partnership (GARDP) and pharmaceutical companies Daiichi Sankyo, Eisai and Takeda, together with Institut Pasteur Korea, an infectious disease-focused research institute, to access and screen the companies' chemical libraries in search of novel antibacterial compounds. The AMR Screening Consortium seeks to accelerate GARDP efforts to identify compounds for development into treatments for drug-resistant infections and supports the pharmaceutical sector in staying engaged in antibiotic research and development.


The Global Antibiotic Research and Development Partnership (GARDP) is a not-for-profit developing new and improved treatments for drug-resistant infections, while working to ensure responsible use and sustainable access. Created by the WHO and Drugs for Neglected Diseases Initiative, GARDP is an essential element of the Global Action Plan on Antimicrobial Resistance.

Global Antibiotic Research & Development Partnership

Related Development Articles from Brightsurf:

What jigsaw puzzles tell us about child development
New research shows that children only learn to do jigsaw puzzles once they have reached a certain stage of development.

Simulating wind farm development
Engineers have devised a model to describe how, in the process of establishing wind farms, interactions between developers and landowners affect energy production costs.

A new approach to measuring inequalities in development
A new study by researchers from IIASA and Hong Kong University of Science and Technology for the first time systematically explored and compared the use of the Human Life Indicator as a viable alternative to the conventional Human Development Index as a means of measuring progress in development.

Reconstructing the clock of human development
Researchers used iPS cells to reconstructed the human 'segmentation clock,' a key point in early embryonic development that determines how the body gets segmented.

Mother nature and child development
A world first review of the importance of nature play could transform children's play spaces, supporting investment in city and urban parks, while also delivering important opportunities for children's physical, social and emotional development.

Citizen science for sustainable development
Monitoring progress on the UN Sustainable Development Goals requires a huge amount of data.

A molecular 'atlas' of animal development
Scientists have studied the nematode worm Caenorhabditis elegans for decades, making essential contributions to basic science.

Novel paradigm in drug development
Targeted protein degradation (TPD) is a new paradigm in drug discovery that could lead to the development of new medicines to treat diseases such as cancer more effectively.

Turbo chip for drug development
In spite of increasing demand, the number of newly developed drugs decreased continuously in the past decades.

New knowledge on the development of asthma
Researchers at Karolinska Institutet in Sweden have studied which genes are expressed in overactive immune cells in mice with asthma-like inflammation of the airways.

Read More: Development News and Development Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to